This study, presented at SNMMI 2025, aimed to further evaluate the safety profile and determine the optimal therapeutic dose of 177 Lu-P17-088, while also exploring its preliminary efficacy in the ...

Dr. Abhilash Moolupuri presented the initial exploratory and phase I/II results of a trial evaluating a novel PSMA-targeting ...

(UroToday.com) The 2025 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting held in New Orleans, LA, was host to an Oncology Discovery and Translational session. Dr. Gary Ulaner ...

In one patient, total body scans were performed at 15 minutes, 1 hour, 2 hours, and 4 hours post-injection. The effective dose was 0.022 mSv/MBq, with the stomach wall receiving the highest organ dose ...

(UroToday.com) The 2025 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting held in New Orleans, LA, was host to an Oncology Discovery and Translational session. Dr. Huipan Liu ...

SNMMI annual meeting featured a prostate cancer session and a presentation by Dr. Sabina Dizdarevic discussing sequencing and combining beta and alpha targeted radionuclide treatments in the ...

The IMPACT-RCC study 7 evaluated visualization of clear cell RCC lesions in 42 patients with metastatic disease (n = 449 lesions). Patients in this study had a lesion size cutoff of 1 cm (lymph nodes ...

The initial insertion of a suprapubic catheter (SPC), a procedure referred to as a suprapubic cystostomy, can be performed under local or general anesthesia with a trocar system, using cystoscopic or ...

(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL between May 30 and June 3 was host to the Poster Session: Genitourinary Cancer - Kidney and ...

(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL between May 30 th and June 3 rd, 2025, was host to a kidney and bladder cancers poster ...

ASCO 2025, Prostate Cancer, androgen deprivation therapy (ADT), HSV-tk gene, Prodrug, intraprostatic injections of CAN-2409, CAN-2409, CAN-2409 plus Prodrug, External Beam Radiation for Newly ...

ASCO 2025 results of AREN1721, phase 2 trial of axitinib + nivolumab combination therapy, nivolumab, TFE/translocation RCC, COG-led NCTN phase 2 trial of nivolumab + axitinib.